ACOG logo

ALPHA COGNITION INC

ACOGNASDAQ
πŸ† #3477 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track ACOG
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$198M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
89.9%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
13.0x
Elevated
Otter Score
β€”
Insufficient data
No chart data available for ACOG.

Trading Snapshot

Day Range
β€”
52-Week Range
$4.50 – $10.14
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
21.8M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$10M
Last Q Revenue
$8M
P/E Ratio
β€”
P/S Ratio
13.0x
EPS (TTM)
$-1.09
Dividend Yield
β€”
Dilution (1yr)
+98.4%
ACOG logo

ALPHA COGNITION INC

ACOG
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$10M
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$23Mβ–² +91.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$21Mβ–² +165.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
22.2Mβ–² +98.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$66Mβ–² +$18M YoY
StockOtter Β· stockotter.space

About ALPHA COGNITION INC

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.